Restoring Immune Function through Thymic Cell Engineering
Developing Scalable Therapies for Aging and Disease
Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company’s cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant-related, and autoimmune disorders.
WHAT IS THE THYMUS?
The thymus is a critical organ for the development and proper function of key parts of the immune system, including T cells, which are essential for fighting infections and other diseases, and play an important role in immune response to vaccines. As part of the natural aging process, the functional thymus begins to shrink and its ability to produce naïve T cells decreases, leading to immune dysfunction and disease.
Recent advances in immunology have led to deeper understanding of the basic processes around thymus function, T cell development and maturation, opening multiple therapeutic frontiers. For example, a recent FDA-approved method enables surgically harvested thymus to restore immune function. The approach, however, faces scalability challenges.
THYMUS (For illustrative purposes only)
OUR PLATFORM
Thymmune’s machine learning-enabled thymic engineering platform allows for the mass production of iPSC-derived thymic cells to restore immune function through a less invasive approach that can be replicated at high quality at scale. Based on decades of research on the thymus gland, Thymmune’s platform has the potential to transform immunology by developing novel therapies for patients with a range of immune system disorders and even address the biology of immune decline for healthier aging.
Meet the Team
-
Stan Wang, MD, PhD
-
Bing Lim, MD, PhD
Research & Development
Henry Beaman, PhD, Scientist
Jacob Dion, R&D Intern
Qiumei Du, PhD, Senior Scientist
Behzad Gerami-Naini, PhD, Senior Scientist
Glenn Michael LaMuraglia, PhD, Senior Scientist
Chloe Lee, Senior Research Associate
Benjamin Schwarz, MD, PhD, Senior Scientist
Rashmi Sridharan, Research Associate
Sarah Thomas, Associate Scientist
Leonardo Velazco, PhD, Senior Scientist
Alec Wishnie, Senior Research Associate
Operations
Thomas McGeggen, Admin /Operations
Catalina Webb, HR
Beth Cirella, Finance
Suzy Dembski, Lab Manager
In the News
-
This is the first industry project funded by the ARPA-H Open Broad Agency Announcement.
-
The biotech startup uses stem cells to develop thymus-rejuvenating therapies.
-
-
Thymmune secures $7 million in seed financing led by Pillar VC, with participation from NYBC Ventures and other investors.
-
The Cambridge, MA-based biotech has raised $7 million in seed funding to push its thymic cell therapy through preclinical studies.
-
Thymmune aims to mass-produce cells to help stave off the degradation of the thymus.
-
Cambridge-based Thymmune has raised $13 million to grow cells from a little-known but crucial immune organ.
-
Join us
At Thymmune, we are passionate about developing best-in-class treatments to improve the lives of patients with immune-mediated diseases.
We have created a collaborative and inclusive environment that thrives on intellectual curiosity and work in a fast-paced environment. We are dedicated to the recruitment, training, and career development of each team member at Thymmune.
To be considered for a position at Thymmune, please submit your CV and cover letter.
Recruitment & Staffing Agencies: Thymmune Therapeutics does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Thymmune or its employees is strictly prohibited unless contacted directly by Thymmune’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Thymmune, and Thymmune will not owe any referral or other fees with respect thereto.